Skip to main content
BAX
NYSE Industrial Applications And Services

Baxter 10-Q Details $253M Debt Gain, $1.07B Cash Flow, New FDA Warning Letter

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Instrument Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$22.936
Mkt Cap
$12.149B
52W Low
$15.73
52W High
$30
52W Position info
46% above low
Off High info
24% below high
Rel. Volume info
2.4× avg
Market data snapshot near publication time

BAX sits 46% above its 52-week low of $15.73 on elevated volume (2.4× avg).

Summary

Baxter's Q3 10-Q confirms $2.98 billion of sales and $0.57 EPS, but shows a $253 million debt-extinguishment gain propping up net income, a 1.1-point gross margin decline excluding special items, and a new FDA Warning Letter at its Round Lake plant.


Key Events · Earnings and Guidance · BAX

  • Q3 Sales $2.98B, EPS $0.57

    Net sales rose 5% to $2,976 million from $2,835 million; net income attributable to Baxter was $294 million, or $0.57 per diluted share, versus a $46 million loss a year ago.

  • $253M Debt Gain Flatters Earnings

    A $253 million pre-tax gain on early extinguishment of debt from the August 2026 tender offers is included in other (income) expense, net; excluding special items, gross margin fell 1.1 points on unfavorable mix and lower pricing.

  • Operating Cash Flow Jumps to $1.07B

    Nine-month cash from continuing operations was $1,068 million versus $355 million a year ago, driven by improved earnings, inventory reduction and better receivables collections.

  • New FDA Warning Letter at Round Lake

    FDA issued a September 2026 Warning Letter following an OAI classification at the Round Lake, Illinois sterile injectable facility; Baxter responded in October 2026 and is implementing corrective actions.


Analysis · BAX · Industrial Applications And Services

The headline numbers were already out this morning, but the full 10-Q carries the pieces that matter for the thesis. A $253 million pre-tax gain on the August tender offers flattered Q3 net income of $294 million — strip that out and the quarter is far thinner, with gross margin down 1.1 points excluding special items on unfavorable mix and weaker pricing. Cash generation is the genuine bright spot: $1.07 billion from continuing operations over nine months versus $355 million a year ago, helped by inventory reduction and better collections. Against that, the company disclosed a September 2026 FDA Warning Letter at its Round Lake sterile injectable plant and responded in October, and it widened its net leverage covenant for five quarters through September 2027 — a sign lenders expect leverage to stay elevated. The dividend is now $0.01 a quarter versus $0.17 a year ago.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BAX was trading at $22.94 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $12.1B. The 52-week trading range was $15.73 to $30.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BAX - Latest Insights

BAX
Oct 29, 2026, 8:06 AM EDT
Source: dpa-AFX
Importance Score:
7
Price at Filing: $26.00
Real-time Price: $25.35 info
Change: -$0.6497 (-2%) info
Market Cap: $13.353B info
BAX
Oct 29, 2026, 7:18 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $26.74
Real-time Price: $25.35 info
Change: -$1.39 (-5%) info
Market Cap: $13.353B info
BAX
Oct 29, 2026, 7:15 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $26.50
Real-time Price: $25.35 info
Change: -$1.15 (-4%) info
Market Cap: $13.353B info
BAX
Aug 19, 2026, 8:07 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $26.20
Real-time Price: $25.35 info
Change: -$0.8497 (-3%) info
Market Cap: $13.353B info
BAX
Aug 18, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $25.88
Real-time Price: $25.35 info
Change: -$0.5297 (-2%) info
Market Cap: $13.353B info